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Abstract 
Bombesin (BB) and gastrin-releasing peptide 
(GRP) bind with high affinity to the GRP-receptor 
(GRP-R) which regulates release of gastrointestinal 
hormones, smooth muscle contraction and 
proliferation of epithelial as well as cancer cells. 
The GRP-R is a G-protein coupled receptor 
(GPCR) which activates phospholipase C signaling 
pathways. The GRP-R is expressed in numerous 
cancers including breast, colon, lung and prostate 
cancer. 
Identity 
HGNC (Hugo): GRPR 
Location: Xp22.2 
DNA/RNA 
Note 
The human GRP-R gene has 3 exons and is 
localized to chromosome Xp22.2. 
Description 
The gene has 3 exons. The GRP-R gene spans 
30218 bases. 
Transcription 
The GRP-R gene has 9 and 3.1 kb transcripts in 
human stomach as well as NCI-H345 lung cancer 
cells, T47D breast cancer cells and HuTu 80 
duodenal carcinoma cells.  
The pancreas has 9, 4.6, 3.1 and 2.1 kb transcripts. 
Polymorphisms are observed at 794 (G-A), 851 (C-
T) and 1061 (C-T) but these do not alter the GRP-R 
sequence (Xiao et al., 2001).  
 
 
The GRP-R gene has 1155 bp. 
Protein 
Note 
Bombesin, a 14 amino acid peptide (Anastasi et al., 
1974) and gastrin-releasing peptide (GRP), a 27 
amino acid peptide (McDonald et al., 1979), bind 
with high affinity to receptors initially characterized 
in the rat brain (Moody et al., 1978) and guinea pig 
pancreatic acini (Jensen et al., 1978).  
The GRP-R was cloned (Battey et al., 1991; 
Spindel et al., 1990) and found to be a G-protein 
coupled receptor (GPCR) containing 384 amino 
acids.  
The human GRP-R gene is localized to the X 
chromosome and the GRP-R has 7 transmembrane 
(TM) domains, an extracellular N-terminal and 
intracellular C-terminal.  
Exon 1 codes for TM 1, 2 and 3 domains with 
splice site in IC loop 2 (Asp137). Exon 2 codes for 
TM 4 and 5 with a Gln255 splice site. Exon 3 codes 
for TM 6-7 domains and the cytoplasmic C-
terminal. Exon 1, 2 and 3 have 413 bp, 352 bp and 
390 bp respectively whereas introns 1 and 2 are 23 
kb and 1.6 kb respectively (Xiao et al., 2001). 
The human GRP-R is glycosylated at Asn20, 
palmitoylated at Cys339 and has a disulfide between 
Cys113 and Cys196 (Jensen et al., 2008). For GRP-R 
agonist binding Gln120, Pro198, Arg287 and Ala307 are 
essential (Akeson et al., 1997). For GRP-R 
antagonist binding Thr296, Phe301 and Ser304 are 
essential (Tokita et al., 2001). GRP-R antagonists 
include (Psi13,14, Leu14)BB, (D-Phe6)BB6-
13propylamide and PD176,252 (Gonzalez et al., 
2009). 
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Human GRP-R protein. The GRP-R, which is a 
glycoprotein embedded in the plasma membrane, contains 
384 amino acids with 7 TM domains, an extracellular N-
terminal and intracellular C-terminal. The amino acids at the 
N- and C-terminal are indicated. The amino acids before 
and after each of the 7 TM domains are indicated. 
Numerous amino acids in or near TM 2, 3, 4, 6 and 7 
domains are essential for agonist binding, whereas amino 
acids in or near TM 6 and 7 domains are important for 
antagonist binding. 
Description 
The GRP-R interacts with Gq causing 
phosphatidylinositol turnover (Rozengurt, 1998). 
As a result, BB addition to small cell lung cancer 
(SCLC) cells causes increased protein kinase C 
activity and elevation of cytosolic Ca2+ (Moody et 
al., 1987). Also, BB causes tyrosine 
phosphorylation of EGFR, ERK, FAK, paxillin, and 
Src leading to increased cellular proliferation 
(Jensen et al., 2008). 
Expression 
The GRP-R is localized to the normal brain 
especially the periventricular nucleus (PVN) of the 
hypothalamus (Wolf et al., 1983) where activation 
by BB causes satiety (Gibbs et al., 1979). The GRP-
R, which regulates insulin secretion, is present in 
the pancreatic islets (Persson et al., 2002). The 
GRP-R is present in colonic villi and may play a 
role in villi development (Carroll et al., 2002). The 
GRP-R is present on small cell lung cancer (SCLC) 
cells and BB stimulates whereas (Psi13,14, Leu14)BB 
or PD176252 inhibits cellular proliferation 
(Mahmoud et al., 1991; Moody et al., 2003). The 
GRP-R is present on squamous cell carcinoma of 
the head and neck cancer cells and PD176252 
inhibits the growth of these cells (Zhang et al., 
2007). In colon cancer the transcription factor 
CREB is a regulator of GRP-R expression 
(Chinnappan et al., 2008). 
Localisation 
The GRP-R is localized to the plasma membrane of 
normal and cancer cells. 
Homology 
Other receptors of the BB family include 
neuromedin B (NMB) which contains 390 amino 
acids (Wada et al., 1991) and has 55% sequence 
homology with the GRP-R.  
An orphan receptor named BB receptor subtype 3 
(BRS-3) was cloned which contains 399 amino 
acids and has 51% sequence homology with the 
GRP-R (Fathi et al., 1993).  
The GRP receptor binds BB and GRP with high 
affinity whereas the NMB receptor binds NMB 
with high affinity.  
BRS-3 does not bind BB, GRP or NMB with high 
affinity (Jensen et al., 2008). 
Mutations 
Note 
The GRP-R gene has 4 point mutations in biopsy 
specimens from patients with autism spectrum 
disorders, 2 of which result in amino acid changes 
(C6S and L181F).  
The mutated GRP-R had normal agonist binding 
and second messenger production (Seidita et al., 
2008).  
Also an X-8 translocation occurs in intron 1 of the 
GRP-R gene in a patient with infantile autism 
(Ishikawa-Brush et al., 1997). 
Implicated in 
Lung cancer 
Note 
High densities of GRP-R are present in SCLC and 
NSCLC biopsy specimens and cell lines (Mattei et 
al., 2014). BB stimulates whereas GRP-R 
antagonists such as PD176252 inhibit lung cancer 
cellular proliferation (Moody et al., 2003). 
Prostate cancer 
Note 
Numerous radioligands have been developed to 
image the GRP-R in prostate cancer patients (Mansi 
et al., 2013; Sancho et al., 2011). GRP-R 
antagonists have been radiolabeled with (111)In, 
(99m)Tc, (68)Ga or (64)Cu (Abiraj et al., 2011). 
High tumor/background ratios were obtained as 
PET and SPECT images. 
Breast cancer 
Note 
Cytotoxic BB conjugates of 2-pyrrolinodoxorubicin 
inhibit the growth of breast cancer xenografts in 
nude mice (Engel et al., 2005). The GRP-R was 
detected in 41/57 breast carcinoma biopsy 
specimens (Reubi et al., 2002). 
Colon cancer 
Note 
The GRPR regulates colon cancer cellular 
differentiation and impairs cellular metastasis 
(Carroll et al., 1999). 
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Head and neck cancer 
Note 
The GRP-R regulates transactivation of the 
epidermal growth factor receptor in head and neck 
squamous cell carcinoma (Lui et al., 2003). The 
mitogenic effects of GRP require the activation of 
an EGFR-dependent MEK/ERK-dependent 
pathway. 
Diabetes 
Note 
GRP-R knockout mice had impaired glucose 
tolerance due to a defect in insulin release (Persson 
et al., 2000). 
Satiety 
Note 
GRP-R blockade antagonizes feeding suppression 
by peripherally administered GRP (Ladenheim et 
al., 1996). 
Hormone secretion 
Note 
The GRP-R regulates the secretion of numerous 
hormones including gastrin, glucagon, insulin, 
pancreatic polypeptide, prolactin and somatostatin 
(Westendorf and Schonbrunn, 1982; Jensen et al., 
2008). 
Pruritus 
Note 
GRP-R containing spinal cord neurons, which are 
present in lamina I, mediate itch sensation (Sun et 
al., 2009). Addition of GRP-R antagonists inhibited 
scratching behavior in 3 mouse models of itching. 
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